<DOC>
	<DOCNO>NCT00675428</DOCNO>
	<brief_summary>The primary objective study evaluate safety profile anti-tumor activity 2 dose level natalizumab participant relapse refractory multiple myeloma . Secondary objective assess pharmacokinetic ( PK ) profile natalizumab study population ass peripheral blood mononuclear cell ( PBMC ) saturation late antigen-4 ( VLA-4 , α4-integrin ) evaluate possible correlation clinical activity .</brief_summary>
	<brief_title>Study Natalizumab Relapsed/Refractory Multiple Myeloma</brief_title>
	<detailed_description>Despite protocol-defined study stop criterion meet , sponsor decide terminate enrollment phase 1 portion complete move phase 2 portion study . This decision make due difficulty enrol participant due safety concern .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Key Relapsed refractory multiple myeloma treat consider inappropriate treatment bortezomib IMiD® drug ( include analogue ) . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤2 . Corrected calcium &lt; 10.6 mg/dL . Key Candidates stem cell transplantation willing undergo transplantation . ( Subjects candidate stem cell transplantation , willing undergo transplant eligible study . ) Autologous stem cell transplantation &lt; 3 month posttransplant . Prior allogeneic stem cell transplantation . Nonsecretory myeloma . Plasma cell leukemia ( &gt; 2000/µL circulate plasma cell standard cell count differential ) , hyperleukocytosis ( white blood cell &gt; 100,000/µL ) , clinical evidence hyperviscosity syndrome , polyneuropathy , organomegaly , endocrinopathy , monoclonal gammopathy , skin change syndrome ( POEMS ) , primary systemic amyloidosis . Subjects undergo brain magnetic resonance imaging ( MRI ) study . Clinically significant ( determined Investigator ) 12 lead electrocardiogram ( ECG ) abnormality , include QTc prolongation ( &gt; 450 m male , &gt; 470 ms female ) . NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Relapsed refractory Multiple Myeloma</keyword>
</DOC>